ASX:BD1

BARD1 LIFE SCIENCES LIMITED

BARD1 LIFE SCIENCES LIMITED has not announced any capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise

$500k - $1m

Investors Interested in Next Raise

< 10

How Fresh Equities Works

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

2. View Terms

View the full term sheet for the capital raise.

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

Company Overview

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Type

Listed Company

GICS Sub-industry

Health Care Services

Head Office

431 Roberts Rd, Subiaco WA 6008, Australia

Website

www.bard1.com

Health Care Services

Health Care

Biotech & Health

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.

Fresh Equities does not have BARD1 LIFE SCIENCES LIMITED quarterly cash flows data.

Directors

Fresh Equities does not have BARD1 LIFE SCIENCES LIMITED directors data.

Announcements

Market Sensitive

From

News

Fresh Equities does not have BARD1 LIFE SCIENCES LIMITED news data.